Практические Рекомендации По Лекарственному Лечению Рака Молочной Железы

Тюляндин, С. А.; Жукова, Л. Г.; Королева, И. А.; Пароконная, А. А.; Семиглазова, Т. Ю.; Стенина, М. Б.; Фролова, М. А.

doi:10.18027/2224-5057-2021-11-3s2-09

Cited by 12 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Локально-регионарные подходы должны включать хирургическое и лучевое лечение. Вторым этапом пациенту была проведена операция в объеме радикальной мастэктомии по Маддену справа и профилактическое удаление левой молочной железы [15,16].…”

Section: онкология и радиология казахстана №4 (66) 2022unclassified

Male Breast Cancer Treatment: A Clinical Case*

Kaidarova

Abdrakhmanova

Dmitrenko

et al. 2022

Onkol. radiol. Kaz.

View full text Add to dashboard Cite

Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrates the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer in the right breast St III (T4NxM0), edematousinfiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3 . Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years.

show abstract

Section: онкология и радиология казахстана №4 (66) 2022unclassified

Male Breast Cancer Treatment: A Clinical Case*

Kaidarova

Abdrakhmanova

Dmitrenko

et al. 2022

Onkol. radiol. Kaz.

View full text Add to dashboard Cite

show abstract

“…Однако необходимо отметить, что в данной возрастной группе чаще, чем в общей популяции больных РМЖ, встречаются более агрессивные фенотипы РМЖ -с гиперэкспрессией HER2/neu и тройной негативный (базальноподобный) фенотип, коррелирующие с более низкими показателями безрецидивной и общей выживаемости [11,14]. Молекулярные подтипы рака молочной железы представлены в таблице [15].…”

Section: Introductionunclassified

CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case

Chekini

Zeynalovа

Ibragimov

et al. 2022

jour

View full text Add to dashboard Cite

Currently, use of CDK4/6 inhibitors in combination with hormone therapy is approved for treatment of patients with advanced or metastatic breast cancer positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2 (HER2). In this clinical observation, analysis of the effectiveness of treatment of a patient with metastatic breast cancer of luminal A subtype is performed. The 1st line combination therapy was CDK4/6 inhibitors (ribociclib) and hormone therapy with aromatase inhibitors (letrozole) and analogues of gonadotropin-releasing hormone (goserelin) with concurrent bone-modifying denosumab therapy. Effectiveness of antitumor drug therapy administered for 7 months, and toxicity of the regimen were evaluated. Effectiveness of the selected combination treatment regimen was demonstrated and confirmed by clinical data, as well as results of laboratory and instrumental examinations. Adverse effects were controlled and managed with symptomatic therapy which allows to continue treatment using previously selected tactics.

show abstract

“…Комбинированная гормонотерапия с ингибиторами ЦЗК 4/6 считается стандартом первых линий лечения метастатического гормонозависимого РМЖ в отсутствие висцерального криза [1][2][3]. К настоящему моменту известны результаты многочисленных исследований, изучавших различные ингибиторы ЦЗК 4/6 в разных клинических ситуациях.…”

Section: Introductionunclassified

Real clinical practice patterns of palbociclib usage in Russian Federation

Фролова

Стенина

2022

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Current treatment of metastatic luminal Her2-negative breast cancer includes combination of endocrine therapy (ET) with CDK4/6 inhibitors. This type of therapy demonstrated impressive efficacy over mono ET in early lines of treatment in phase III randomized clinical trials. Treatment patterns in real clinical practice (RCP) are of great interest. We represent the first available local data for all CDK 4/6 inhibitors in RCP in Russian Federation in accordance with the number of patients (pts).Aim. Analysis of the patterns of palbociclib administration in RCP.Materials and methods. One hundred and 5 pts from 12 regions of Russian Federation were included in this analysis and received palbociclib in combination with ET from 2017 to 2020. Median age was 57 years (29-75), 31/105 (29.5%) of pts were < 50. De novo metastatic disease was observed in 16 (15.2%) pts, 89 pts progressed after radical treatment. Visceral metastases (mts) at palbociclib initiation had 61/105 (58.1%) of pts.Results. Only 22/105 (21%) of pts received palbociclib as 1st line treatment of metastatic disease. The majority of pts was treated with palbociclib in 2nd and 3rd lines (28.5% and 30.5% respectively). In 26/105 (24.8%) pts palbociclib was combined with aromatase inhibitors, in other cases - with fulvestrant. Median follow-up time was 6.5 (1.1-31.9) months, median progression free survival - 6.0 (1.0-28.0) months. Most common adverse events (AE) were leukopenia, neutropenia and thrombocytopenia. Only in 3 cases palbociclib was completely stopped due to toxicity.Conclusions. Our data indicates that there is a need to move palbociclib initiation in first two lines of treatment to get maximal improvement in survival and to increase its usage in young women.

show abstract

Практические Рекомендации По Лекарственному Лечению Рака Молочной Железы

Abstract: .

Cited by 12 publications

References 0 publications

Male Breast Cancer Treatment: A Clinical Case*

Male Breast Cancer Treatment: A Clinical Case*

CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case

Real clinical practice patterns of palbociclib usage in Russian Federation

Contact Info

Product

Resources

About